Drugs / soblidotin
soblidotin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00072228 | — | — | Daiichi Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00061854 | Apr 2003 → May 2005 | lung cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00064220 | Apr 2003 → Dec 2005 | sarcoma | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | soblidotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00072228 ↗ |
| Known as | Auristatin pe | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989512 ↗ |
| Known as | Soblidotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989512 ↗ |
| Known as | Soblidotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989512 ↗ |
| Known as | TZT-1027 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989512 ↗ |
| Action | Inhibit | “blocks cells during G2/M-phase by interfering with microtubule assembly and stability.” PMID 17109446 ↗ Dec 2006 |
| Modality | Small molecule | — CHEMBL3989512 ↗ |
| Route | Intravenous | “Patients receive soblidotin IV over 1 hour on days 1 and 8.” NCT00061854 ↗ |